Chronogesic DURECT

IDrugs

Volumn 6, Issue 4, 2003, Pages 368-371

  Joshi, Girish P ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; FENTANYL; LEUPRORELIN; METHADONE; MORPHINE; OPIATE; OXYCODONE; RECOMBINANT INTERLEUKIN 2; SUFENTANIL;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTHRITIS; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DROWSINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG IMPLANT; DRUG MANUFACTURE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOXICITY; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; IN VIVO STUDY; LOW BACK PAIN; MULTICENTER STUDY; NAUSEA; NECK PAIN; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SLEEP DISORDER; STRUCTURE ACTIVITY RELATION; URINE RETENTION; VERTIGO; VOMITING;

ANALGESICS, OPIOID; ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG IMPLANTS; HUMANS; PAIN; STRUCTURE-ACTIVITY RELATIONSHIP; SUFENTANIL;

EID: 0038706566     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. 82806 Sufentanil: A review of its pharmacological properties and therapeutic use. Monk JP, Beresford R, Ward A Drugs 1988 36 3 286-313
2. 358478 ALZA announces approval of Viadur for once-yearly palliative treatment of advance prostate cancer - First 12-month dosing regimen provides uninterrupted testosterone. ALZA Corp Press Release 2000 March 06
3. 376335 DURECT Corporation receives $20 million in second round of funding. DURECT Corp Press Release 1999 August 02
4. 393204 DURECT Corporation enrolls patients in phase II clinical trial for DUROS Sufentanil. DURECT Corp Press Release 2000 December 11
5. 398169 DURECT announces acceleration of completion of patient enrollment in its phase II clinical trial for DUROS Sufentanil. DURECT Corp Press Release 2001 February 07
6. 414192 DURECT announces chronogesic preliminary clinical results of phase II trial. DURECT Corp Press Release 2001 July 01
7. 421080 DURECT announces positive phase II results on chronogesic for long-term pain relief. DURECT Corp Press Release 2001 September 05
8. 427716 DURECT Corporation reports initiation of phase III program for Chronogesic. DURECT Corp Press Release 2001 November 01
9. 443909 DURECT Corporation announces positive results of pilot phase III study for the Chronogesic product. DURECT Corp Press Release 2002 March 18
10. 457407 DURECT initiates pivotal phase III program for the Chronogesic (sufentanil) pain therapy system. DURECT Corp Press Release 2002 July 09
11. 462473 DURECT Corporation delays enrolling additional patients in its phase III clinical trial for Chronogesic pending clinical trial protocol amendments. DURECT Corp Press Release August 26
12. 465848 Pharmacokinetic characteristics of Chronogesic, an implanted osmotic system delivering sufentanil. Fisher DM, Kellett N, Lenhardt R World Congr Pain August 17-22 Abs 198-P-194
13. 469801 Endo Pharmaceuticals and DURECT Corporation agree to collaborate on treatment in pain management. Endo Pharmaceuticals Inc/DURECT Corp Press Release November 11
14. 474166 System functionality and physicochemical model of fentanyl transdermal system. Gupta SK, Southam M, Gale R, Hwang SS J Pain Symptom Manage 1992 7 Suppl 3 S17-S26
15. 474167 Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Bruera E, Brenneis C, Michaud M, Bacovsky R, Chadwick S, Emeno A, MacDonald N Cancer 1988 62 2 407-411
16. 474169 Biotransformation of sufentanil in liver microsomes of rats, dogs, and humans. Lavrijsen K, Van Houdt J, Van Dyck D, Hendrickx J, Lauwers W, Hurkmans R, Bockx M, Janssen C, Meuldermans W, Heykants J Drug Metab Dispos 1990 18 5 704-710
17. 474481 A pilot study, review of literature, and dosing guidelines for patient-controlled analgesia using subcutaneous morphine sulphate for chronic cancer pain. Walsh TD, Smyth EMS, Currie K, Glare PA, Schneider J Palliative Med 1992 6 217-226
18. 474490 Sufentanil and medetomidine anaesthesia in the rat and its reversal with atipamezole and butorphanol. Hedenqvist P, Roughan JV, Flecknell PA Lab Anim 2000 34 3 244-251
19. 474494 Current management of opioid-related side effects. O'Mahoney S, Coyle N, Payne R Oncology 2001 15 1 61-73
20. 475979 Durect Corporation. Hambrecht & Quist January 6-9 132-133
21. 476274 Analgetic contribution of sufentanil during halothane anethesia: A mechanism involving serotonin. Althaus JS, Miller ED Jr, Moscicki JC, Hecker BR, DiFazio CA Anesth Analg 1985 64 9 857-863
22. 478099 Durect: In-line 4Q: Chronogesic remains on target for 2H03. Goodman M, Nachman G, Bhalla A Morgan Stanley Dean Witter 2003 January 29